Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 5/20 | 0.46 |
| ▸ | JAK2 | O60674 | 4/20 | 0.46 |
| ▸ | TYK2 | P29597 | 4/20 | 0.46 |
| ▸ | JAK3 | P52333 | 4/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL177126 | 0.98 | PDPK1 (0.53) | PDPK1HSP90AB1ESR1JAK1JAK2 | |
| Tert-Butyl Formate SCHEMBL27819466 | 0.85 | PDPK1 (0.41) | PDPK1HSP90AB1ESR1JAK1JAK2 | |
| SCHEMBL130781 | 0.80 | ITK (0.47) | MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6 | |
| SCHEMBL10189221 | 0.80 | KIF11 (0.47) | FGFR1GSK3BALDH1A1GAAHPGD | |
| SCHEMBL6543491 | 0.79 | HTR2C (0.48) | PDPK1HSP90AB1ESR1JAK1JAK2 | |
| SCHEMBL2553028 | 0.79 | HTR2C (0.48) | PDPK1HSP90AB1ESR1JAK1JAK2 | |
| SCHEMBL7587263 | 0.79 | HTR2C (0.48) | PDPK1HSP90AB1ESR1JAK1JAK2 | |
| SCHEMBL5677771 | 0.79 | MAP2K4 (0.51) | GSK3BMAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL16095565 | 0.79 | AXL (0.50) | PDPK1JAK2FGFR1FGFR2GSK3B | |
| SCHEMBL5790250 | 0.79 | PDE3B (0.36) | PDPK1HSP90AB1JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102171192-A | Indazole compounds | ASAHI KASEI PHARMA CORP | 2011-08-31 | — | — | CN | claimed |
| EP-2345644-A1 | INDAZOLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-07-20 | — | — | EP | claimed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | claimed |
| EP-2831061-A1 | TRIAZOLE DERIVATIVES AS HSP90 INHIBITORS | Synta Pharmaceuticals Corp. (US) | 2015-02-04 | — | — | EP | disclosed |
| WO-2013148857-A1 | TRIAZOLE DERIVATIVES AS HSP90 INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2484668-A1 | INDAZOLE ANALOGUE | Asahi Kasei Pharma Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| CN-102171192-A | Indazole compounds | ASAHI KASEI PHARMA CORP | 2011-08-31 | — | — | CN | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2345644-A1 | INDAZOLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-07-20 | — | — | EP | disclosed |
| WO-2011040510-A1 | INDAZOLE ANALOGUE | 旭化成ファーマ株式会社 (JP) | 2011-04-07 | — | — | WO | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ADRB3, ADRB1, ADRB2 | PDPK1 1131/4885HSP90AB1 793/4885ESR1 1355/4885 |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | GPR119, ADRB1, ADRA1A | PDPK1 1068/4885HSP90AB1 777/4885ESR1 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.